International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors

Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing accuracy, standardized quality criteria must be clearly defined and universally implemented. The Intern...

Descripció completa

Dades bibliogràfiques

Autors principals:	Nicola Fusco, Konstantinos Venetis, Francesco Pepe, Omshree Shetty, Silvia Calabuig Farinas, Simon Heeke, Julia V. Burnier, Simon J. Patton, Ellen Heitzer, Giovanni Nigita, Paul Hofman, Maria Jose Serrano, Massimo Cristofanilli, Eloisa Jantus-Lewintre, David R. Gandara, Christian Rolfo, Umberto Malapelle
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-06-01
Col·lecció:	The Journal of Liquid Biopsy
Matèries:	Circulating tumor DNA (ctDNA) Precision oncology Standardization Quality assurance Liquid biopsy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2950195425000177
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!